v3.26.1
COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2022
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2022
Apr. 30, 2025
Schedule of License and Collaboration Agreements [Line Items]                    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001     $ 0.0001   $ 0.0001 $ 0.0001    
Total revenue   $ 0 $ 212   $ 212 $ 424 $ 858 $ 636    
Research and development   758 6,074   3,629 11,799 19,597 41,507    
AbCellera Collaboration                    
Schedule of License and Collaboration Agreements [Line Items]                    
Research and development             0 400    
License                    
Schedule of License and Collaboration Agreements [Line Items]                    
Total revenue             800 600    
License Agreement | Sanofi                    
Schedule of License and Collaboration Agreements [Line Items]                    
Upfront payment       $ 3,000            
Aggregate development and regulatory milestone payments             43,000      
Obligation to payment upon maximum achievement of certain clinical and commercial milestones             150,000      
License Agreement | Sanofi | License Rights                    
Schedule of License and Collaboration Agreements [Line Items]                    
Transaction costs associated with asset acquisition                 $ 100  
License Agreement | Sanofi | License Rights | IPR&D                    
Schedule of License and Collaboration Agreements [Line Items]                    
Research and development             0 0 $ 3,100  
Collaboration and license revenue                    
Schedule of License and Collaboration Agreements [Line Items]                    
Total revenue   $ 0 $ 212   $ 212 $ 424 $ 858 $ 636    
Johnson & Johnson | Securities Purchase Agreement                    
Schedule of License and Collaboration Agreements [Line Items]                    
Sale of stock, number of shares issued in transaction (in shares) 454,545                  
Sale of stock, price per share (in dollars per share) $ 14.56                  
Sale of stock, premium on stock price (as a percent) 10.00%                  
Gross proceeds $ 6,600                  
Allocated amounts 1,200                  
Johnson & Johnson | Securities Purchase Agreement | Fair Value, Nonrecurring                    
Schedule of License and Collaboration Agreements [Line Items]                    
Fair value 5,400                  
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Premium                    
Schedule of License and Collaboration Agreements [Line Items]                    
Allocated amounts 700                  
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Discount for Lack of Marketability                    
Schedule of License and Collaboration Agreements [Line Items]                    
Allocated amounts $ 500                  
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Price Volatility | Fair Value, Nonrecurring                    
Schedule of License and Collaboration Agreements [Line Items]                    
Measurement input 1.132                  
Johnson & Johnson | Securities Purchase Agreement | Measurement Input, Risk Free Interest Rate | Fair Value, Nonrecurring                    
Schedule of License and Collaboration Agreements [Line Items]                    
Measurement input 0.0528                  
Johnson & Johnson | License                    
Schedule of License and Collaboration Agreements [Line Items]                    
Collaboration agreement term 2 years                  
Upfront payment                   $ 500
Johnson & Johnson | License Agreement                    
Schedule of License and Collaboration Agreements [Line Items]                    
Collaboration agreement term 2 years